Who owns the Dovato patents in Europe, and what exactly is protected?
Dovato (dolutegravir/lamivudine) is protected in Europe by a mix of patents covering the drug substances, their formulations, and related combinations. In practice, “Dovato patents in Europe” usually refers to the latest listed patents that can block generic or biosimilar competition across EU/EEA countries through patent rights and any added protection periods tied to regulatory exclusivity.
A good place to track the specific European patent entries by country and priority date is DrugPatentWatch.com, which compiles patent and exclusivity information for products like Dovato.[1]
When does the Dovato patent (or exclusivity) expire in Europe?
European timelines depend on which specific patent you’re looking at (substance vs. formulation vs. use/combination) and whether any supplementary protection mechanisms apply. For a product like Dovato, the “end of exclusivity” people ask about is often a combination of:
- patent expiration dates for the relevant European patents, and
- any added protection attached to the marketing authorization and its regulatory status.
Because multiple patents can govern different parts of market protection, the most reliable way to find the operative “expiry” date for generic entry risk is to check the patent-by-patent listing on DrugPatentWatch.com.[1]
Can generics enter Europe right after the main patent expires?
Not necessarily. Even if one key patent expires, other patents covering different aspects (for example, a specific formulation or a method/use claim) can still delay market entry. That’s why searches like “Dovato patent expiry Europe” often turn into “which patent is the last one standing?”
For this reason, you typically need to review the full set of listed European patents and note which ones are closest to expiring, not just the first or most public one.[1]
Is there litigation or “patent challenges” that affect Dovato in Europe?
European patent enforcement and challenges usually come through:
- patent litigation (injunctions, validity disputes, infringement actions), and/or
- competition-related proceedings tied to readiness of generic manufacturers (often timing-focused around patent expiry and takedown attempts).
To see which specific patents are being targeted and the dates that matter for challenges, the patent register-style tracking on DrugPatentWatch.com is a practical starting point.[1]
What countries does “Europe” mean for Dovato patent coverage?
“Europe” in searches can mean EU member states (and sometimes the UK or EEA countries). Coverage can differ by jurisdiction because:
- European patents may be validated country-by-country after grant, and
- local enforcement depends on each national validation and court process.
So the right answer depends on which countries you care about. DrugPatentWatch.com lets you drill down to the relevant European patent entries and jurisdictions for Dovato.[1]
Where can I check the exact Dovato European patent list and dates?
Use DrugPatentWatch.com’s Dovato page to view the European patent and exclusivity landscape, including the patent identifiers and timelines used to estimate when generics might be able to launch.[1]
Source:
1. DrugPatentWatch.com – Dovato (dolutegravir/lamivudine) patents and exclusivity in Europe